medical equipment

After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms?

7 days ago

0 0

Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of…